HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT (Diffusing Alpha Radiation Therapy),’ developed by Alpha Tau Medical Ltd. (Headquarters: Jerusalem, Israel) has received official approval in Japan. HekaBio led the approval process as the Designated Marketing Authorization Holder (DMAH) and will be responsible for launching the product in the Japanese market.With this approval, Japan becomes the first country in the world outside

IntraBio Inc. today announced that a positive opinion recommending Orphan Medicinal Product Designation for Acetylleucine for the treatment of CACNA1A disorders has been granted by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). The European Commission is expected to grant the designation in Q2 2026. CACNA1A-related disorders are rare, genetic neurological conditions characterized by progressive impairment in coordination, balance, speech, and overall

Feb. 23, 2026 -- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced today a new research partnership with the University of Louisville that will evaluate the impact of a combination therapy of surgical intervention and immunotherapy in three different cancers, including colorectal, liver, and pancreatic. As part of the collaboration, the University of Louisville will be analyzing live

Feb. 25, 2026 -- Abram Scientific, a medical device company focused on advancing next-generation coagulation diagnostics, today announced the closing of a $11.75 million Series A financing round. The round was led by global pharmaceutical leader Octapharma AG, with additional participation from existing and new investors affiliated with University of Colorado Anschutz. This funding will accelerate the development of Abram Scientific's proprietary portable platform, CoagCare™, for aiding the eva

Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagement Results are published in the 7 January issue of the Journal of Inherited Metabolic Disease Nizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today ann

Feb. 25, 2026 -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026. GPP is a rare, chronic, life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema, and systemic symptoms such as fever and

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™- Feb. 24, 2026 -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platfor drug optimization technology, today

Feb. 25, 2026 -- Melodia Therapeutics AG today announced that the United States Patent and Trademark Office (USPTO) has granted a key U.S. patent covering a structurally novel DPP1 (Cathepsin C) inhibitor, currently developed as MLD-151 by Melodia Therapeutics and discovered by its partner, Alivexis, Inc., strengthening the intellectual property foundation supporting Melodia's lead development program. The newly issued patent (U.S. Patent No. 12,522,593; International Application No. PCT/JP2023

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 i

GSK said it will acquire a 100% equity stake in Canadian clinical-stage biotech 35Pharma for $950 million in cash, securing rights to the latter's lead asset — an activin signalling inhibitor (ASI) being developed for pulmonary hypertension (PH). "We're delighted to add HS235 to our pipeline, a potential best-in-class medicine with a differentiated profile to reduce risk of bleeding and provide potential metabolic benefits clinically relevant to PH patients," said Tony Wood, chief scientific of